Arcutis Biotherapeutics, Inc. (ARQT) Stock Competitors & Peer Comparison
See (ARQT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARQT | $28.26 | +2.65% | 3.5B | -942.00 | -$0.03 | N/A |
| VRTX | $482.00 | +0.31% | 122.3B | 25.61 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $675.19 | +0.45% | 69.6B | 14.80 | $45.63 | +0.54% |
| ARGX | $874.74 | +3.37% | 54.4B | 78.95 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $183.29 | +1.61% | 39B | -25.93 | -$7.07 | N/A |
| RVMDW | $8.86 | +2.90% | 37.8B | -2.13 | -$4.15 | N/A |
| ALNY | $271.37 | -0.48% | 36.2B | 48.90 | $5.55 | N/A |
| ONC | $318.69 | +2.61% | 34.1B | 71.29 | $4.47 | N/A |
Stock Comparison
ARQT vs VRTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, VRTX has a market cap of 122.3B. Regarding current trading prices, ARQT is priced at $28.26, while VRTX trades at $482.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas VRTX's P/E ratio is 25.61. In terms of profitability, ARQT's ROE is -0.01%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ARQT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check VRTX's competition here
ARQT vs VRNA Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARQT is priced at $28.26, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARQT's ROE is -0.01%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ARQT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check VRNA's competition here
ARQT vs REGN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, REGN has a market cap of 69.6B. Regarding current trading prices, ARQT is priced at $28.26, while REGN trades at $675.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas REGN's P/E ratio is 14.80. In terms of profitability, ARQT's ROE is -0.01%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ARQT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check REGN's competition here
ARQT vs ARGX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ARGX has a market cap of 54.4B. Regarding current trading prices, ARQT is priced at $28.26, while ARGX trades at $874.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ARGX's P/E ratio is 78.95. In terms of profitability, ARQT's ROE is -0.01%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ARQT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ARGX's competition here
ARQT vs SGEN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARQT is priced at $28.26, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARQT's ROE is -0.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARQT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check SGEN's competition here
ARQT vs RVMD Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RVMD has a market cap of 39B. Regarding current trading prices, ARQT is priced at $28.26, while RVMD trades at $183.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RVMD's P/E ratio is -25.93. In terms of profitability, ARQT's ROE is -0.01%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ARQT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check RVMD's competition here
ARQT vs RVMDW Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RVMDW has a market cap of 37.8B. Regarding current trading prices, ARQT is priced at $28.26, while RVMDW trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RVMDW's P/E ratio is -2.13. In terms of profitability, ARQT's ROE is -0.01%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ARQT is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check RVMDW's competition here
ARQT vs ALNY Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ALNY has a market cap of 36.2B. Regarding current trading prices, ARQT is priced at $28.26, while ALNY trades at $271.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ALNY's P/E ratio is 48.90. In terms of profitability, ARQT's ROE is -0.01%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ARQT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ALNY's competition here
ARQT vs ONC Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ONC has a market cap of 34.1B. Regarding current trading prices, ARQT is priced at $28.26, while ONC trades at $318.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ONC's P/E ratio is 71.29. In terms of profitability, ARQT's ROE is -0.01%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ARQT is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ONC's competition here
ARQT vs ROIV Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, ARQT is priced at $28.26, while ROIV trades at $34.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ROIV's P/E ratio is -35.93. In terms of profitability, ARQT's ROE is -0.01%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ARQT is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check ROIV's competition here
ARQT vs MRNA Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MRNA has a market cap of 23.7B. Regarding current trading prices, ARQT is priced at $28.26, while MRNA trades at $59.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MRNA's P/E ratio is -7.32. In terms of profitability, ARQT's ROE is -0.01%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ARQT is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check MRNA's competition here
ARQT vs INSM Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, INSM has a market cap of 23.5B. Regarding current trading prices, ARQT is priced at $28.26, while INSM trades at $108.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas INSM's P/E ratio is -18.89. In terms of profitability, ARQT's ROE is -0.01%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ARQT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check INSM's competition here
ARQT vs INCY Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, ARQT is priced at $28.26, while INCY trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas INCY's P/E ratio is 15.78. In terms of profitability, ARQT's ROE is -0.01%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ARQT is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check INCY's competition here
ARQT vs BNTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, ARQT is priced at $28.26, while BNTX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas BNTX's P/E ratio is -19.98. In terms of profitability, ARQT's ROE is -0.01%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ARQT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check BNTX's competition here
ARQT vs UTHR Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, UTHR has a market cap of 22.7B. Regarding current trading prices, ARQT is priced at $28.26, while UTHR trades at $535.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas UTHR's P/E ratio is 19.76. In terms of profitability, ARQT's ROE is -0.01%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ARQT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check UTHR's competition here
ARQT vs BGNE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARQT is priced at $28.26, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARQT's ROE is -0.01%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ARQT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check BGNE's competition here
ARQT vs DNA-WT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARQT is priced at $28.26, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARQT's ROE is -0.01%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ARQT is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check DNA-WT's competition here
ARQT vs NBIX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, NBIX has a market cap of 18B. Regarding current trading prices, ARQT is priced at $28.26, while NBIX trades at $179.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas NBIX's P/E ratio is 25.87. In terms of profitability, ARQT's ROE is -0.01%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ARQT is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check NBIX's competition here
ARQT vs GMAB Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, GMAB has a market cap of 17.4B. Regarding current trading prices, ARQT is priced at $28.26, while GMAB trades at $28.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas GMAB's P/E ratio is 20.41. In terms of profitability, ARQT's ROE is -0.01%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ARQT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check GMAB's competition here
ARQT vs BBIO Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, BBIO has a market cap of 16.1B. Regarding current trading prices, ARQT is priced at $28.26, while BBIO trades at $82.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas BBIO's P/E ratio is -22.05. In terms of profitability, ARQT's ROE is -0.01%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ARQT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check BBIO's competition here
ARQT vs JAZZ Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, ARQT is priced at $28.26, while JAZZ trades at $254.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas JAZZ's P/E ratio is 19.77. In terms of profitability, ARQT's ROE is -0.01%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ARQT is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check JAZZ's competition here
ARQT vs ASND Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ASND has a market cap of 15.9B. Regarding current trading prices, ARQT is priced at $28.26, while ASND trades at $255.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ASND's P/E ratio is -105.45. In terms of profitability, ARQT's ROE is -0.01%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ARQT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ASND's competition here
ARQT vs EXEL Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, ARQT is priced at $28.26, while EXEL trades at $56.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas EXEL's P/E ratio is 16.80. In terms of profitability, ARQT's ROE is -0.01%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ARQT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check EXEL's competition here
ARQT vs MDGL Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, ARQT is priced at $28.26, while MDGL trades at $546.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MDGL's P/E ratio is -42.72. In terms of profitability, ARQT's ROE is -0.01%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ARQT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check MDGL's competition here
ARQT vs KRTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARQT is priced at $28.26, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARQT's ROE is -0.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARQT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check KRTX's competition here
ARQT vs AXSM Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, AXSM has a market cap of 12.2B. Regarding current trading prices, ARQT is priced at $28.26, while AXSM trades at $236.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas AXSM's P/E ratio is -61.87. In terms of profitability, ARQT's ROE is -0.01%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ARQT is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check AXSM's competition here
ARQT vs BMRN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, ARQT is priced at $28.26, while BMRN trades at $59.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas BMRN's P/E ratio is 28.47. In terms of profitability, ARQT's ROE is -0.01%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ARQT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check BMRN's competition here
ARQT vs SMMT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, SMMT has a market cap of 11.4B. Regarding current trading prices, ARQT is priced at $28.26, while SMMT trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas SMMT's P/E ratio is -9.14. In terms of profitability, ARQT's ROE is -0.01%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ARQT is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check SMMT's competition here
ARQT vs RNAM Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARQT is priced at $28.26, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARQT's ROE is -0.01%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ARQT is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check RNAM's competition here
ARQT vs TECH Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ARQT is priced at $28.26, while TECH trades at $71.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas TECH's P/E ratio is 36.92. In terms of profitability, ARQT's ROE is -0.01%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ARQT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check TECH's competition here
ARQT vs ARWR Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, ARQT is priced at $28.26, while ARWR trades at $74.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ARWR's P/E ratio is -34.66. In terms of profitability, ARQT's ROE is -0.01%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ARQT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ARWR's competition here
ARQT vs CYTK Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CYTK has a market cap of 10.1B. Regarding current trading prices, ARQT is priced at $28.26, while CYTK trades at $81.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CYTK's P/E ratio is -13.91. In terms of profitability, ARQT's ROE is -0.01%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ARQT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CYTK's competition here
ARQT vs KRYS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, ARQT is priced at $28.26, while KRYS trades at $339.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas KRYS's P/E ratio is 45.33. In terms of profitability, ARQT's ROE is -0.01%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARQT is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check KRYS's competition here
ARQT vs ABVX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ABVX has a market cap of 9.8B. Regarding current trading prices, ARQT is priced at $28.26, while ABVX trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ABVX's P/E ratio is -70.29. In terms of profitability, ARQT's ROE is -0.01%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ARQT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ABVX's competition here
ARQT vs RXDX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARQT is priced at $28.26, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARQT's ROE is -0.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check RXDX's competition here
ARQT vs KYMR Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, KYMR has a market cap of 9.3B. Regarding current trading prices, ARQT is priced at $28.26, while KYMR trades at $113.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas KYMR's P/E ratio is -32.12. In terms of profitability, ARQT's ROE is -0.01%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ARQT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check KYMR's competition here
ARQT vs HALO Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, HALO has a market cap of 9.3B. Regarding current trading prices, ARQT is priced at $28.26, while HALO trades at $78.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas HALO's P/E ratio is 17.01. In terms of profitability, ARQT's ROE is -0.01%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ARQT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check HALO's competition here
ARQT vs NUVL Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARQT is priced at $28.26, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARQT's ROE is -0.01%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARQT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check NUVL's competition here
ARQT vs PTGX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, PTGX has a market cap of 8.9B. Regarding current trading prices, ARQT is priced at $28.26, while PTGX trades at $138.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas PTGX's P/E ratio is -76.41. In terms of profitability, ARQT's ROE is -0.01%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ARQT is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check PTGX's competition here
ARQT vs CRNX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ARQT is priced at $28.26, while CRNX trades at $83.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CRNX's P/E ratio is -16.35. In terms of profitability, ARQT's ROE is -0.01%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARQT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CRNX's competition here
ARQT vs IONS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, IONS has a market cap of 8.8B. Regarding current trading prices, ARQT is priced at $28.26, while IONS trades at $53.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas IONS's P/E ratio is -31.04. In terms of profitability, ARQT's ROE is -0.01%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ARQT is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check IONS's competition here
ARQT vs ALKS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, ARQT is priced at $28.26, while ALKS trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ALKS's P/E ratio is 55.63. In terms of profitability, ARQT's ROE is -0.01%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ARQT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ALKS's competition here
ARQT vs IMGN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARQT is priced at $28.26, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARQT's ROE is -0.01%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARQT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check IMGN's competition here
ARQT vs IBRX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, ARQT is priced at $28.26, while IBRX trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas IBRX's P/E ratio is -9.49. In terms of profitability, ARQT's ROE is -0.01%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ARQT is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check IBRX's competition here
ARQT vs PCVX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, ARQT is priced at $28.26, while PCVX trades at $58.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas PCVX's P/E ratio is -8.44. In terms of profitability, ARQT's ROE is -0.01%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ARQT is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check PCVX's competition here
ARQT vs BPMC Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARQT is priced at $28.26, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARQT's ROE is -0.01%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check BPMC's competition here
ARQT vs APGE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ARQT is priced at $28.26, while APGE trades at $134.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas APGE's P/E ratio is -30.99. In terms of profitability, ARQT's ROE is -0.01%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ARQT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check APGE's competition here
ARQT vs TGTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, ARQT is priced at $28.26, while TGTX trades at $53.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas TGTX's P/E ratio is 18.53. In terms of profitability, ARQT's ROE is -0.01%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ARQT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check TGTX's competition here
ARQT vs CERE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARQT is priced at $28.26, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARQT's ROE is -0.01%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARQT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CERE's competition here
ARQT vs IMVT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, ARQT is priced at $28.26, while IMVT trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas IMVT's P/E ratio is -14.81. In terms of profitability, ARQT's ROE is -0.01%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ARQT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check IMVT's competition here
ARQT vs MTSR Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARQT is priced at $28.26, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARQT's ROE is -0.01%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ARQT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check MTSR's competition here
ARQT vs RYTM Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, ARQT is priced at $28.26, while RYTM trades at $106.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RYTM's P/E ratio is -34.06. In terms of profitability, ARQT's ROE is -0.01%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ARQT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check RYTM's competition here
ARQT vs MRUS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARQT is priced at $28.26, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARQT's ROE is -0.01%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ARQT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check MRUS's competition here
ARQT vs COGT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, ARQT is priced at $28.26, while COGT trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas COGT's P/E ratio is -18.79. In terms of profitability, ARQT's ROE is -0.01%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ARQT is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check COGT's competition here
ARQT vs ACLX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARQT is priced at $28.26, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARQT's ROE is -0.01%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ARQT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ACLX's competition here
ARQT vs PRAX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, ARQT is priced at $28.26, while PRAX trades at $317.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas PRAX's P/E ratio is -23.77. In terms of profitability, ARQT's ROE is -0.01%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ARQT is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check PRAX's competition here
ARQT vs RETA Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARQT is priced at $28.26, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARQT's ROE is -0.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARQT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check RETA's competition here
ARQT vs PTCT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, ARQT is priced at $28.26, while PTCT trades at $78.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas PTCT's P/E ratio is -33.68. In terms of profitability, ARQT's ROE is -0.01%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ARQT is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check PTCT's competition here
ARQT vs BLTE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ARQT is priced at $28.26, while BLTE trades at $161.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas BLTE's P/E ratio is -86.14. In terms of profitability, ARQT's ROE is -0.01%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ARQT is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check BLTE's competition here
ARQT vs CGON Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ARQT is priced at $28.26, while CGON trades at $71.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CGON's P/E ratio is -30.78. In terms of profitability, ARQT's ROE is -0.01%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ARQT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CGON's competition here
ARQT vs CNTA Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARQT is priced at $28.26, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARQT's ROE is -0.01%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARQT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CNTA's competition here
ARQT vs SYRE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, ARQT is priced at $28.26, while SYRE trades at $102.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas SYRE's P/E ratio is -49.37. In terms of profitability, ARQT's ROE is -0.01%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ARQT is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check SYRE's competition here
ARQT vs LGND Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, ARQT is priced at $28.26, while LGND trades at $305.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas LGND's P/E ratio is 36.63. In terms of profitability, ARQT's ROE is -0.01%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ARQT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check LGND's competition here
ARQT vs SRRK Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, SRRK has a market cap of 6.1B. Regarding current trading prices, ARQT is priced at $28.26, while SRRK trades at $50.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas SRRK's P/E ratio is -14.17. In terms of profitability, ARQT's ROE is -0.01%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ARQT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check SRRK's competition here
ARQT vs ERAS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ERAS has a market cap of 6B. Regarding current trading prices, ARQT is priced at $28.26, while ERAS trades at $19.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ERAS's P/E ratio is -20.84. In terms of profitability, ARQT's ROE is -0.01%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ARQT is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check ERAS's competition here
ARQT vs MIRM Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, ARQT is priced at $28.26, while MIRM trades at $117.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MIRM's P/E ratio is -8.60. In terms of profitability, ARQT's ROE is -0.01%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ARQT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check MIRM's competition here
ARQT vs CDTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARQT is priced at $28.26, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARQT's ROE is -0.01%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ARQT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CDTX's competition here
ARQT vs ABCM Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $28.26, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARQT's ROE is -0.01%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARQT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ABCM's competition here
ARQT vs ISEE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $28.26, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARQT's ROE is -0.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARQT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ISEE's competition here
ARQT vs XENE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $28.26, while XENE trades at $66.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas XENE's P/E ratio is -14.20. In terms of profitability, ARQT's ROE is -0.01%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ARQT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check XENE's competition here
ARQT vs TVTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $28.26, while TVTX trades at $56.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas TVTX's P/E ratio is -257.18. In terms of profitability, ARQT's ROE is -0.01%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ARQT is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check TVTX's competition here
ARQT vs APLS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $28.26, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARQT's ROE is -0.01%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARQT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check APLS's competition here
ARQT vs DFTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, ARQT is priced at $28.26, while DFTX trades at $45.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARQT's ROE is -0.01%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ARQT is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check DFTX's competition here
ARQT vs TERN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARQT is priced at $28.26, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARQT's ROE is -0.01%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ARQT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check TERN's competition here
ARQT vs CRSP Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ARQT is priced at $28.26, while CRSP trades at $48.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CRSP's P/E ratio is -9.42. In terms of profitability, ARQT's ROE is -0.01%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ARQT is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check CRSP's competition here
ARQT vs MANE Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, ARQT is priced at $28.26, while MANE trades at $109.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MANE's P/E ratio is -34.71. In terms of profitability, ARQT's ROE is -0.01%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ARQT is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check MANE's competition here
ARQT vs FOLD Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARQT's ROE is -0.01%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ARQT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check FOLD's competition here
ARQT vs AKRO Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARQT's ROE is -0.01%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ARQT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check AKRO's competition here
ARQT vs CELC Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26, while CELC trades at $91.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CELC's P/E ratio is -23.51. In terms of profitability, ARQT's ROE is -0.01%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ARQT is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check CELC's competition here
ARQT vs ALPN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $28.26, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARQT's ROE is -0.01%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARQT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ALPN's competition here
ARQT vs CAI Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ARQT is priced at $28.26, while CAI trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CAI's P/E ratio is -86.52. In terms of profitability, ARQT's ROE is -0.01%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ARQT is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check CAI's competition here
ARQT vs DNTH Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, ARQT is priced at $28.26, while DNTH trades at $105.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas DNTH's P/E ratio is -25.60. In terms of profitability, ARQT's ROE is -0.01%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ARQT is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check DNTH's competition here
ARQT vs VKTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, ARQT is priced at $28.26, while VKTX trades at $37.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas VKTX's P/E ratio is -9.17. In terms of profitability, ARQT's ROE is -0.01%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ARQT is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check VKTX's competition here
ARQT vs ACAD Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ARQT is priced at $28.26, while ACAD trades at $25.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ACAD's P/E ratio is 12.47. In terms of profitability, ARQT's ROE is -0.01%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ARQT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check ACAD's competition here
ARQT vs LEGN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, LEGN has a market cap of 4.4B. Regarding current trading prices, ARQT is priced at $28.26, while LEGN trades at $23.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas LEGN's P/E ratio is -34.62. In terms of profitability, ARQT's ROE is -0.01%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ARQT is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check LEGN's competition here
ARQT vs EWTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ARQT is priced at $28.26, while EWTX trades at $39.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas EWTX's P/E ratio is -23.84. In terms of profitability, ARQT's ROE is -0.01%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ARQT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check EWTX's competition here
ARQT vs OPT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $28.26, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARQT's ROE is -0.01%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARQT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check OPT's competition here
ARQT vs MRTX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARQT is priced at $28.26, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARQT's ROE is -0.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARQT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check MRTX's competition here
ARQT vs DYN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, ARQT is priced at $28.26, while DYN trades at $23.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas DYN's P/E ratio is -7.40. In terms of profitability, ARQT's ROE is -0.01%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ARQT is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check DYN's competition here
ARQT vs ELVN Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ARQT is priced at $28.26, while ELVN trades at $54.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ELVN's P/E ratio is -32.53. In terms of profitability, ARQT's ROE is -0.01%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ARQT is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check ELVN's competition here
ARQT vs CPRX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARQT is priced at $28.26, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ARQT's ROE is -0.01%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARQT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CPRX's competition here
ARQT vs DNLI Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $28.26, while DNLI trades at $23.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas DNLI's P/E ratio is -8.27. In terms of profitability, ARQT's ROE is -0.01%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ARQT is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check DNLI's competition here
ARQT vs NAMS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $28.26, while NAMS trades at $32.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas NAMS's P/E ratio is -20.34. In terms of profitability, ARQT's ROE is -0.01%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ARQT is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check NAMS's competition here
ARQT vs RYZB Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $28.26, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARQT's ROE is -0.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARQT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check RYZB's competition here
ARQT vs CBAY Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $28.26, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARQT's ROE is -0.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARQT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check CBAY's competition here
ARQT vs ALMS Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ALMS has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $28.26, while ALMS trades at $30.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ALMS's P/E ratio is -7.67. In terms of profitability, ARQT's ROE is -0.01%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, ARQT is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check ALMS's competition here
ARQT vs TLX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $28.26, while TLX trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas TLX's P/E ratio is -593.48. In terms of profitability, ARQT's ROE is -0.01%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ARQT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ARQT.Check TLX's competition here
ARQT vs ADPT Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ARQT is priced at $28.26, while ADPT trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas ADPT's P/E ratio is -41.81. In terms of profitability, ARQT's ROE is -0.01%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, ARQT is less volatile compared to ADPT. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check ADPT's competition here
ARQT vs TNGX Comparison July 2026
ARQT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.5B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, ARQT is priced at $28.26, while TNGX trades at $29.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of -942.00, whereas TNGX's P/E ratio is -34.96. In terms of profitability, ARQT's ROE is -0.01%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ARQT is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for ARQT.Check TNGX's competition here